Across TCGA pan-cancer cohorts, CHST2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CHST2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CHST2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CHST2 is over-expressed in tumor.
CCRCC and HNSC are the cancer types where CHST2 tumor–normal differential expression is most reproducible.